Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples